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A B S T R A C T
Background
Pilonidal sinus disease is a common condition thatmainly affects young adults. This condition can cause significant pain and impairment
of normal activities. No consensus currently exists on the optimum treatment for pilonidal sinus and current therapies have various
advantages and disadvantages. Fibrin glue has emerged as a potential treatment as both monotherapy and an adjunct to surgery.
Objectives
To assess the effects of fibrin glue alone or in combination with surgery compared with surgery alone in the treatment of pilonidal sinus
disease.
Search methods
In December 2016 we searched: the Cochrane Wounds Specialised Register; CENTRAL; MEDLINE; Embase and CINAHL Plus.
We also searched clinical trials registries and conference proceedings for ongoing and unpublished studies and scanned reference lists
to identify additional studies. There were no restrictions with respect to language, date of publication or study setting.
Selection criteria
We included randomised controlled trials (RCTs) only. We included studies involving participants of all ages and studies conducted in
any setting. We considered studies involving people with both new and recurrent pilonidal sinus. We included studies which evaluated
fibrin glue monotherapy or as an adjunct to surgery.
Data collection and analysis
Two study authors independently extracted data and assessed risk of bias. We used standard methods expected by Cochrane.
Main results
We included four RCTs with 253 participants, all were at risk of bias. One unpublished study evaluated fibrin glue monotherapy
compared with Bascom’s procedure, two studies evaluated fibrin glue as an adjunct to Limberg flap and one study evaluated fibrin glue
as an adjunct to Karydakis flap.
For fibrin glue monotherapy compared with Bascom’s procedure, there were no data available for the primary outcomes of time to
healing and adverse events. There was low-quality evidence of less pain on day one after the procedure with fibrin glue monotherapy
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compared with Bascom’s procedure (mean difference (MD) -2.50, 95% confidence interval (CI) -4.03 to -0.97) (evidence downgraded
twice for risk of performance and detection bias). Fibrin glue may reduce the time taken to return to normal activities compared with
Bascom’s procedure (mean time 42 days with surgery and 7 days with glue, MD -34.80 days, 95% CI -66.82 days to -2.78 days) (very
low-quality evidence, downgraded as above and for imprecision).
Fibrin glue as an adjunct to the Limberg flap may reduce the healing time from 22 to 8 days compared with the Limberg flap alone
(MD -13.95 days, 95% CI -16.76 days to -11.14 days) (very low-quality evidence, downgraded twice for risk of selection, performance
and detection bias and imprecision). It is uncertain whether use of fibrin glue affects the incidence of postoperative seroma (an adverse
event) (risk ratio (RR) 0.27, 95% CI 0.05 to 1.61; very low-quality evidence, downgraded twice for risk of selection, performance and
detection bias and imprecision). There was low-quality evidence that fibrin glue, as an adjunct to Limberg flap, may reduce postoperative
pain (median 2 versus 4; P < 0.001) and time to return to normal activities (median 8 days versus 17 days; P < 0.001). The addition
of fibrin glue to the Limberg flap may reduce the length of hospital stay (MD -1.69 days, 95% CI -2.08 days to -1.29 days) (very low-
quality evidence, downgraded twice for risk of selection, performance and detection bias and for unexplained heterogeneity).
A single RCT evaluating fibrin glue as an adjunct to the Karydakis flap did not report data for the primary outcome of time to healing.
It is uncertain whether fibrin glue with the Karydakis flap affects the incidence of postoperative seroma (adverse event) (RR 3.00,
95% CI 0.67 to 13.46) (very low-quality evidence, downgraded twice for risk of selection, performance and detection bias and for
imprecision). Fibrin glue as an adjunct to Karydakis flap may reduce length of stay but this is highly uncertain (mean 2 days versus 3.7
days; P < 0.001, low-quality evidence downgraded twice for risk of selection, performance and detection bias).
Authors’ conclusions
Current evidence is uncertain regarding any benefits associated with fibrin glue either as monotherapy or as an adjunct to surgery for
people with pilonidal sinus disease. We identified only four RCTs and each was small and at risk of bias resulting in very low-quality
evidence for the primary outcomes of time to healing and adverse events. Future studies should enrol many more participants, ensure
adequate randomisation and blinding, whilst measuring clinically relevant outcomes.
P L A I N L A N G U A G E S U M M A R Y
Fibrin glue for pilonidal sinus disease
Review question
We reviewed the evidence regarding the effectiveness of fibrin glue, used on its own or with surgery, in the treatment of pilonidal sinus
disease.
Background
Pilonidal sinus disease is a common condition mainly affecting young adults. The condition develops following an infection in the
groove between the buttocks. The infection can cause fluid collections or a sinus (a channel under the skin) to form. Young men are
more likely to be affected, and other risk factors include obesity, poor hygiene and prolonged sitting. Extensive body hair is also a factor
as ingrowing hair follicles are thought to make the condition worse. The condition causes pain and often requires time off work. This
affects patients’ quality of life and may cause loss of earnings.
Pilonidal sinus disease is normally treated with a small operation. Fibrin glue, a naturally-occurring glue-like gel, can also be used as an
alternative to, or in addition to surgery. We looked for evidence as to whether fibrin glue can speed up the healing time for this type of
wound. We also wanted to find out if the treatment affected other outcomes such as pain, infection and return of the pilonidal sinus
following the procedure, and whether it had any side effects (fluid collections or allergic reactions).
Study characteristics
In December 2016 we searched for randomised controlled trials involving participants of any age or sex, whose pilonidal sinus had
been treated with fibrin glue, either on its own or with surgery. We found four studies that included 253 participants, the majority
of whom were male. Fibrin glue on its own was compared with surgery in one study. In three studies fibrin glue was applied during
surgery and compared with surgery on its own. There were problems with the design and conduct of all four studies which mean that
their results are very uncertain.
Key results
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It is not known whether fibrin glue on its own affects time to healing and adverse events compared with a type of surgery (Bascom’s
procedure). Fibrin glue may result in less pain on the first day after the procedure compared with Bascom’s procedure.
When fibrin glue is used alongside a type of surgery called the Limberg flap it may reduce the healing time by approximately 14 days
compared with the surgery on its own, however this finding is highly uncertain as the evidence is very low-quality. It is uncertain
whether using the fibrin glue alongside the Limberg flap affects the incidence of a complication called seroma (a collection of fluid) but
it may reduce postoperative pain (this evidence is low-quality and therefore quite uncertain) and may reduce time to return to normal
activities (low-quality evidence) and length of hospital stay (this was very low-quality evidence and therefore very uncertain).
One study evaluated the effect of adding fibrin glue to a type of surgery called the Karydakis flap. It is not clear from this study whether
using the glue affects time to healing or the incidence of seroma. Using the fibrin glue with the Karydakis flap may reduce length of
hospital stay compared with surgery alone but again this is low-quality evidence.
Quality of the evidence
The quality of evidence for all outcomes was low or very low, mainly due to problems with the ways the studies were conducted and
also the uncertainty in the results because of the small numbers of participants in the studies. This means we cannot be confident of
the effects of fibrin glue on any of these outcomes and more, better quality and larger studies are required.
This plain language summary is up to date as of December 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fibrin glue compared with Bascom’s procedure for pilonidal sinus
Patient or population: adults with pilonidal sinus
Settings: secondary care
Intervention: f ibrin glue
Comparison: Bascom’s procedure
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Bascom’s procedure Fibrin glue
Time to healing (days) Not reported
Adverse events
(seroma or allergic re-
action)
Not reported
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
Pilonidal sinus disease is a common condition and mainly affects
young adults. The term pilonidal derives from the Latin words for
hair (pilus) and nest (nidus) and was first described by Mayo in
1833 (Mayo 1833). Pilonidal sinus is an acquired disease, which
results in obstruction of hair follicles in the natal cleft (the anatom-
ical groove between the buttocks), a commonly affected area. Sub-
sequent rupture of the follicles leads to abscess and sinus forma-
tion. This condition is further exacerbated by ingrown loose hairs
into these sinuses (Hull 2002; Karydakis 1992). In one Norwe-
gian study, the estimated incidence of pilonidal sinus was 26 per
100,000 of the population (Søndenaa 1995). The mean age at
consultation is 29 years inmen and25 years inwomen.Risk factors
for development of the condition include male gender, extensive
body hair, young adulthood, family history, local trauma, seden-
tary lifestyle, poor hygiene, an anatomically deep natal cleft and
obesity (Akinci 1999; Søndenaa 1995; Thompson 2010). Apart
from the health considerations, there is also an economic impli-
cation for healthcare systems and society in managing this condi-
tion.
The ideal management of pilonidal sinus disease should be sim-
ple, cost-effective, easy to perform and lead to a rapid return to
normal activities, with low rates of infection and recurrence, and
rapid wound healing. Acute presentation with pilonidal abscess
is treated with simple incision and drainage. However, one pa-
tient in five will experience recurrent symptoms (Jensen 1988).
Chronic pilonidal sinus disease presents as recurrent episodes of
infection, pain and discharge from the natal cleft. There is no con-
sensus as yet on the management of pilonidal sinus disease, but
all interventions are surgical and are split, in broad terms, into
two strategies: excision without closure to allow healing through
secondary intention (wound left open) or excision with primary
closure (wound closed at the time of surgery). A Cochrane Re-
view in 2010 showed that healing through secondary intention
had lower recurrence rates compared with primary closure (risk
ratio (RR) 0.65, 95% confidence interval (CI) 0.46 to 0.93) but
at the expense of longer healing times (41 to 120 days in heal-
ing through secondary intention versus 10 to 27 days in primary
closure) (Al-Khamis 2010). For people who undergo primary clo-
sure there is a clear benefit in terms of rates of recurrence if it is
performed through off-midline closure (wound lying adjacent to
the natal cleft) versus midline closure (wound lying within the na-
tal cleft) (Enriquez-Navascues 2014). Commonly performed off-
midline closure techniques include the Karydakis flap, Bascom II
technique, and Rhomboid and Limberg flaps; however, the results
are variable. Although these flap techniques have low recurrence
and infection rates, they may lead to complications and signifi-
cantly delayed return to employment (Thompson 2010).
Description of the intervention
Fibrin glue may offer an alternative to surgery in the definitive
treatment of pilonidal sinus disease. The glue has been used for a
variety of applications over the last 15 years (Spotnitz 2010), in-
cluding anal fistulas (Sentovich 2003), skin grafts (Currie 2001),
and haemostasis (an intervention that stops the bleeding process)
(Rutgeerts 1997). Treatment costs are dependent on volume and
brand although treatment costs are typically low (approximately
GBP200per treatment). The fibrin glue is composed of fibrinogen
and thrombin, causing formation of a fibrin clot within the sinus.
Studies suggest few complications (0% to 12.5%), low recurrence
rates (0% to 17%) (Handmer 2012), early return to normal activi-
ties (Lund 2005; Patti 2006), and high levels of patient satisfaction
(Elsey 2013). However, these are often small observational studies
and therefore conclusions are limited. Complications may include
seromas and wound breakdown (Handmer 2012). Many previous
studies have used fibrin glue as an adjunct to surgical treatment,
for example, to close dead space (a cavity remaining after closure
of a wound) in primary closure techniques. However, fibrin glue
as monotherapy may be an alternative intervention to surgery for
pilonidal sinus disease.
How the intervention might work
Thrombin within the glue mixture converts fibrinogen to fibrin,
forming a fibrin clot within the sinus. Both thrombin and fibrin
are normal blood products produced during the blood clotting
process. This may reduce dead space within the sinus and pro-
mote healing without the need for invasive surgical excision and
associated wound-healing complications, and thus allow a faster
return to normal activities.
Why it is important to do this review
Consensus on the optimal treatment for pilonidal sinus disease is
lacking. There are a wide variety of techniques, each with advan-
tages and disadvantages. As found in a previous Cochrane review,
more invasive procedures lead to less recurrence at the expense
of delayed recovery time and slower healing (Al-Khamis 2010).
Therefore, no current treatment satisfies the criteria for an ideal
therapy for pilonidal sinus disease. Fibrin glue is a less invasive,
novel monotherapy that has shown promise in observational stud-
ies. However, evidence from randomised controlled trials is re-
quired, as this is the optimum method to assess the effects of this
intervention. Previous systematic reviews have included both ob-
servational studies and randomised controlled trials and no data
fromunpublished studies (Handmer 2012; Kayaalp 2016). There-
fore, a rigorous summary of the evidence is required to determine
whether fibrin glue should be more widely used for treating pi-
lonidal sinus disease.
5Fibrin glue for pilonidal sinus disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
O B J E C T I V E S
To assess the effects of fibrin glue alone or in combination with
surgery compared with surgery alone in the treatment of pilonidal
sinus disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) only.
Types of participants
We included all ages of participants in the review. There was no
restriction on the setting in which the treatment was delivered.
We considered studies including both new and recurrent pilonidal
sinus.
Types of interventions
Fibrin glue (any brand containing a mixture of fibrinogen and
thrombin, human or bovine) compared with other surgical tech-
niques such as primary closure, closure through secondary inten-
tion and off-midline closure techniques. We also included trials
if they used fibrin glue as an adjunct to surgery (compared with
surgery alone).
Types of outcome measures
Primary outcomes
• Healing (time to wound healing in days)
• Adverse events (seroma and allergic reaction).
Secondary outcomes
• Infection - surgical site infection (SSI) (proportion of
pilonidal sinus surgical sites infected during follow-up as
reported in the study)
• Recurrence - of treated pilonidal sinus as opposed to a new
pilonidal sinus at another site (proportion of treated pilonidal
sinus that recurred during follow-up as reported in the study)
• Postoperative or post-procedural pain (measured using a
validated scale such as a visual analogue scale (VAS))
• Time to return to normal activities (days)
• Quality of life (measured using validated scales such as SF-
36, EQ-5D or the Cardiff Wound Impact Schedule)
• Cost difference (of treatment, postoperative care and loss of
employment in GBP or USD)
• Length of stay in hospital (days).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify relevant
RCTs:
• the Cochrane Wounds Specialised Register (searched 13
December 2016);
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, issue 12) in the Cochrane Library;
• Ovid MEDLINE (including Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE
Daily) (1946 to 13 December 2016);
• Ovid Embase (1974 to 13 December 2016);
• EBSCO CINAHL Plus (1937 to 13 December 2016).
The search strategies forCENTRAL,OvidMEDLINE,OvidEm-
base and EBSCOCINAHL Plus can be found in Appendix 1. We
did not combine the topic-specific searches with any RCT filters as
the number of search results were low. There were no restrictions
with respect to language, date of publication or study setting.
We also searched the following clinical trials registries (searched
December 2016):
• ClinicalTrials.gov;
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP)
• EU Clinical Trials Register.
Searching other resources
There was no language restriction in the search and, where nec-
essary, we translated non-English language papers using Google
Translate. We sought grey literature from OpenSIGLE. We
searched conference proceedings from the last three years (Asso-
ciation of Coloproctology of Great Britain and Ireland, European
Society of Coloproctology, Royal Society of Medicine Coloproc-
tology Section and American Society of Colon and Rectal Sur-
geons). We handsearched reference lists of identified studies for
other suitable papers. We utilised Google Scholar to identify pa-
pers that had cited identified studies.
Data collection and analysis
We conducted data analysis using Review Manager 5 (RevMan 5)
(RevMan 2014) according to methods stipulated in the published
review protocol (Lund 2015).
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Selection of studies
Two review authors independently matched studies to the inclu-
sion and exclusion criteria (BD and JPW) and, if any disagree-
ment existed, a third review author was consulted and we reached
agreement by consensus. We extracted the titles and abstracts of
potentially relevant studies onto an electronic database and these
underwent full-text review with duplicates being removed. We
used full-text reports to match against the inclusion and exclusion
criteria. We used the kappa statistic to measure agreement during
the selection process. We identified duplicate publications of the
same studies by using author names, study location, intervention
details and cohort dates. We planned to link any duplicate pub-
lications. As one review author had authored one of the included
studies (JL), we performed selection of studies using two different
authors to reduce bias.
Data extraction and management
Two review authors independently collected and extracted data
into an electronic database (BD and ST). As one review author
had authored one of the included studies, we performed data ex-
traction using two different authors to reduce bias. We then com-
pared the data and resolved discrepancies by checking the original
study. We stored data on a password-protected computer. If any
information was not reported, we contacted the study authors for
further information.
Where possible we extracted the following data:
• bibliographic data including date of completion/
publication;
• country of origin;
• publication status of study;
• source of funding for trial;
• trial design;
• care setting;
• number of participants randomised to each trial arm and
number included in final analysis;
• eligibility criteria and key baseline participant data
including category(s) and location(s) of sinus;
• details of treatment regimen received by each group;
• duration of treatment;
• details of any co-interventions;
• primary and secondary outcome(s) (with definitions and,
where applicable, time points);
• outcome data for primary and secondary outcomes (by
group);
• duration of follow-up;
• number of withdrawals (by group) and number of
withdrawals (by group) due to adverse events;
• adverse events.
Assessment of risk of bias in included studies
Two study authors (BD and ST) assessed risk of bias indepen-
dently and a third author resolved any disagreements (JPW). We
used the Cochrane tool for assessing risk of bias (Appendix 2;
Higgins 2011a).We recorded sequence generation, allocation con-
cealment, blinding of participants, personnel and outcome asses-
sors, incomplete outcome data, selective outcome reporting and
other sources of bias. We assigned each study low, high or unclear
risk of bias using published criteria (Higgins 2011a). To assess se-
lective outcome reporting, we searched clinical trials databases for
the original study registration and compared this with the pub-
lished study. In terms of blinding, we recognised that this would be
difficult to implement fully as in other surgical studies. However,
blinding of outcome assessment was deemed possible in studies
comparing fibrin glue as an adjunct to surgery. We presented risk
of bias data in a summary table and ’Risk of bias’ graph.
Measures of treatment effect
We presented dichotomous outcomes as risk ratios (RR). We pre-
sented continuous outcomes as mean differences (MD) if scales
were comparable or standardised mean differences (SMD) if non-
comparable scales were used. We would have reported time-to-
event data as hazard ratios (HR). If HR were not reported, we
would have estimated these using the events in each group and
derived the P value from the log rank test (Tierney 2007). Where
time to healing was wrongly reported as a continuous outcome
(as opposed to a time-to-event outcome) and we were not able to
derive hazard ratios we endeavoured to find out whether all par-
ticipants had healed and we planned to exclude such data from
meta-analyses.
Unit of analysis issues
As the person was the unit of analysis and they are likely to have
only one pilonidal sinus, there were no unit of analysis issues (
Higgins 2011b).
Dealing with missing data
If studies withmissing data were identified, we contacted the study
authors. If we received no response, we extracted data from pub-
lished graphs if appropriate. If standard deviations were not re-
ported, we estimated these from other studies in the review. We
used the most clinically similar study to the one with missing val-
ues for these estimates. We did not use methods of imputation for
missing participant data.
Assessment of heterogeneity
We assessed clinical heterogeneity during the data extraction pro-
cess, especially the trial methods and baseline demographics. If sig-
nificant clinical heterogeneity was present, we did not pool studies
and discussed them in the narrative review. For statistical hetero-
geneity, we used the I2 statistic (Higgins 2003). We pooled data
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using the fixed-effect model in the first instance. If substantial het-
erogeneity was present, we pooled data using the random-effects
model. We used the following cut-off values for the I2 statistic
(Deeks 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We assessed selective reporting bias as part of the Cochrane ’Risk
of bias’ tool. We planned to assess publication bias qualitatively
using funnel plots and quantitatively using Egger’s regression test
if 10 studies or more were included in the analysis (Sterne 2011).
However, the low number of included studies precluded this.
Data synthesis
We presented meta-analysis as forest plots if methods were similar
enough that data synthesis was deemed appropriate. If not appro-
priate, we performed qualitative synthesis. We did not estimate
missing data onmeasures of central tendency from reported values
(mean estimated from median). We contacted study authors to
provide any missing values. We combined continuous outcomes
using generic inverse variance from the standard errors. We com-
bined risk ratios using the Mantel-Haenszel method. We used a
fixed-effect model if there was no heterogeneity. If heterogeneity
was present, we used the random-effects model (Deeks 2011).
’Summary of findings’ table
We have presented the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to each
of the main outcomes using the GRADE approach, which defines
the quality of a body of evidence as the extent to which one can
be confident that an estimate of effect or association is close to the
true quantity of specific interest. The quality of a body of evidence
involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias (Schünemann 2011b). Evi-
dence from RCTs is downgraded from high quality to moderate,
low or very lowquality if any of the above uncertainties are present.
We have presented the following outcomes in the ’Summary of
findings’ tables:
• time to healing (days);
• adverse events (seroma and/or allergic reaction).
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analysis and meta-regression.
However, the small number of included studies precluded this.
Sensitivity analysis
We planned to conduct a sensitivity analysis excluding studies that
we judged high risk of bias for any of the ’Risk of bias’ assessments
and those sponsored by pharmaceutical companies. If sensitivity
analysis results differed substantially, we would have carefully in-
terpreted the final results.
R E S U L T S
Description of studies
Results of the search
We identified 38 studies from searching of electronic databases
(Figure 1) and a further two records from searching clinical trials
databases and conference proceedings. However, these were dupli-
cate records from the same study (Lund 2010). Further informa-
tion was requested and provided from one of the review authors
(JL). We considered four studies to be eligible for inclusion in the
final review.
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Figure 1. Study flow diagram
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Included studies
We included four RCTs with 253 participants (Characteristics of
included studies; Altinli 2007; Lund 2010; Sözen 2011a; Sözen
2011b). One study was published in abstract form only (Lund
2010). The kappa statistic showed perfect agreement for inclu-
sion of studies when performed in duplicate (κ = 1 by BD and
JPW). One study examined fibrin glue compared with Bascom’s
procedure (Lund 2010), two studies examined fibrin glue as an
adjunct to Limberg flap (Altinli 2007; Sözen 2011b) and one
study examined fibrin glue as an adjunct to Karydakis flap (Sözen
2011a). The interventions used were 1 ml to 2 ml of Tisseel fib-
rin glue in one study (Lund 2010) and 6 ml of Cryoseal FS Sys-
tem fibrin glue in three studies (Altinli 2007; Sözen 2011a; Sözen
2011b). In two of the studies, only the control group received
postoperative drains (Sözen 2011a; Sözen 2011b). All studies were
conducted in adults and three studies included men only (Altinli
2007; Sözen 2011a; Sözen 2011b). All studies were conducted
in a secondary care setting. One study was conducted in the UK
(Lund 2010) and three studies were conducted in Turkey (Altinli
2007; Sözen 2011a; Sözen 2011b). None of the included studies
reported sources of funding. The number of participants in the
studies were 32 (Altinli 2007), 39 (Lund 2010), 50 (Sözen 2011a)
and 132 (Sözen 2011b).
One study reported the following outcomes: drainage volume,
length of stay, proportion of wounds infected, seroma (adverse
event) and mortality (Altinli 2007). One unpublished study re-
ported: pain, quality-of-life scores, analgesia usage, recurrence, in-
fection, time to return to normal mobility and employment and
cost reduction compared with surgery (Lund 2010). One study
reported: length of stay, seroma and recurrence (Sözen 2011a).
The final study reported: postoperative pain, time to first mobili-
sation, length of stay, time to return to employment, infection, flap
oedema, wound dehiscence, seroma, healing time and duration
of surgery (Sözen 2011b). Units of measurement can be found
in the characteristics of included studies tables (Characteristics of
included studies). Follow-up in the included studies were: mean
8.5 months and 8.2 months (intervention and control group re-
spectively) (Altinli 2007), median 4.6 years (Lund 2010), median
10.2 months (Sözen 2011a) and mean 2 months and 6 months
(intervention and control group respectively) (Sözen 2011b). The
methods of outcome assessment were not reported in one study
(Altinli 2007). One study reported that a questionnaire was used
to assess duration of recovery and that participants were followed
up weekly until wounds had healed then every three months for
one year (Sözen 2011b). One study followed up participants with
physical examination at one month then six monthly thereafter
(Sözen 2011a). One study measured outcomes at one and six
weeks in clinic (Lund 2010). Due to the differences between the
Karydakis and Limberg procedures, we did not pool data from
these different surgical approaches together. The Karydakis proce-
dure involves an off-midline elliptical incision, whilst the Limberg
procedure involves a rhomboid incision with a flap constructed
from an additional lateral incision. Moreover, previous research
has shown differing outcomes for these surgical techniques mak-
ing separate comparisons more clinically appropriate (Bali 2015).
Excluded studies
We excluded five studies that were not RCTs (Characteristics of
excluded studies; Greenberg 2004; Isik 2014; Lund 2005; Patti
2006; Seleem 2005).
Risk of bias in included studies
We performed ’Risk of bias’ assessments using the Cochrane tool
for assessing risk of bias (Higgins 2011a). We regarded all the
included studies as being at high risk of bias. The assessments for
each study can found in Figure 2 and Figure 3. Details on the
criteria for assessing risk of bias can be found in Appendix 2.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Two studies randomised participants on the basis of an admission
protocol number and therefore were classified at high risk of bias
for randomisation and unclear risk for allocation concealment, as
there was not enough information to determine whether alloca-
tion of participants from this protocol number could be foreseen
(Sözen 2011a; Sözen 2011b). One study randomised participants
on the basis of the day they were first seen in clinic and therefore
we regarded it as being at high risk of bias for both randomisa-
tion and allocation concealment (Altinli 2007). One study used
computer-generated randomisation and allocated participants us-
ing sequentially-numbered, sealed opaque envelopes and therefore
was assessed as low risk for both domains (Lund 2010).
Blinding
None of the included studies used a placebo substitute for fibrin
glue. Two studies used postoperative drains in the control group
but not the fibrin glue group and were therefore regarded as high
risk for performance and detection bias (Sözen 2011a; Sözen
2011b). One study did not have differential use of postoperative
drains although the care-giver was not blinded so we regarded at
high risk for performance bias and unclear risk for detection bias,
as no details were provided on outcome assessment (Altinli 2007).
One study used fibrin glue monotherapy compared with surgery
(Bascom’s procedure) and therefore could not be blinded, so we
classified it at high risk for performance and detection bias (Lund
2010).
Incomplete outcome data
Three studies did not report any participants lost to follow-up
and therefore we regarded them to be at low risk of bias for this
domain (Altinli 2007; Sözen 2011a; Sözen 2011b). One study lost
one participant to follow-up in the control group; this study was
classified as low risk, as it was not thought this would significantly
bias the results obtained (Lund 2010).
Selective reporting
Only one study registered on a clinical trials database and healing
was pre-stated on registration although not reported in a published
abstract so we regarded this as high risk of bias (Lund 2010). We
could not identify any published clinical trials registration for the
three other studies and we regarded all these as being at unclear
risk of bias for this domain (Altinli 2007; Sözen 2011a; Sözen
2011b).
Other potential sources of bias
Three studies had similar baseline characteristics and no other risks
of bias and therefore we classified them at low risk for this domain
(Altinli 2007; Lund 2010; Sözen 2011a). One study had different
lengths of follow-up in the fibrin and control groups (mean follow-
up two months and six months respectively) and therefore was
classified at high risk for this domain (Sözen 2011b).
Effects of interventions
See: Summary of findings for the main comparison Fibrin glue
compared with Bascom’s procedure for pilonidal sinus; Summary
of findings 2Limberg flapplus fibrin glue comparedwith Limberg
flap for pilonidal sinus; Summary of findings 3 Karydakis flap
plus fibrin glue compared with Karydakis flap and drain for
pilonidal sinus
Fibrin glue versus Bascom’s procedure (one RCT, 39
participants)
Primary outcomes
Healing
This outcome was not reported in the included study. Further
data showed that all wounds had healed at follow-up (median 11
months) although there were no data to calculate time to healing.
Adverse events
These outcomes were not reported in the included study.
Secondary outcomes
Infection
We included one unpublished study with 39 participants in this
outcome (Lund 2010). It is uncertain whether there was a differ-
ence in infection rates at a median follow-up of 11 months with
fibrin glue when compared with Bascom’s procedure (RR 0.57,
95% CI 0.16 to 2.06) (Analysis 1.1). The quality of evidence was
very low-quality according to GRADE (downgraded twice for risk
of bias and for imprecision).
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Recurrence
The same unpublished study (39 participants) reported this out-
come (Lund 2010). It is uncertain whether there was a difference
in the proportion of participants suffering a recurrence of their
pilonidal sinus within a median follow-up period of 11 months
(RR 0.95, 95% CI 0.06 to 14.13). The quality of evidence was
very low (downgraded twice for risk of bias and for imprecision).
It is also uncertain whether there was a difference on longer-term
follow-up (median 4.6 years) in the same study (Lund 2010) (RR
1.43, 95% CI 0.27 to 7.61) (Analysis 1.2; very low-quality evi-
dence downgraded twice for risk of bias and for imprecision).
Pain
The same unpublished study (39 participants) reported this out-
come (Lund 2010). This study measured pain on an 11-point
scale, from day one to day seven after the procedure however we
report results from day one as this a standard time to measure pain
in trials of postoperative analgesics. Fibrin glue may reduce pain
on day one after the procedure (MD -2.50, 95% CI -4.03 to -
0.97) (Analysis 1.3), measured on an 11-point scale. The quality
of evidence was low (downgraded twice for risk of bias).
Time to return to normal activities
The same unpublished study (39 participants) reported this out-
come (Lund 2010). Fibrin glue may reduce the time to return
to employment compared with Bascom’s procedure (MD -34.80
days, 95% CI -66.82 days to -2.78 days) (Analysis 1.4), however
this finding is highly uncertain. The quality of evidence was very
low (downgraded twice for risk of bias and for imprecision).
Quality of life
The same unpublished study (39 participants) reported this out-
come (Lund 2010). It is uncertain whether fibrin glue leads to an
improvement in quality of life at day seven, measured using the
EQ-5D scale (MD 8.00, 95% CI -0.10 to 16.10) (Analysis 1.5).
The quality of evidence was very low (downgraded twice for risk
of bias and for imprecision).
Cost difference
The same unpublished study (39 participants) reported this out-
come (Lund 2010). Non-reporting of standard deviations or costs
in each group precluded inclusion in the analysis. The study re-
ported a cost reduction of GBP 1120 (USD 1623) in the fibrin
glue participants compared with participants in the Bascom’s pro-
cedure group.
Length of stay
This outcome was not reported in the included study.
Limberg flap with and without fibrin glue (two RCTs,
164 participants)
Primary outcomes
Healing
One study (132 participants) reported this outcome (Sözen
2011b) as time to healing, albeit wrongly regarding time to heal-
ing as a continuous outcome. We were able to discern from the
published data that all participants healed and therefore all con-
tributed data to the analysis. Fibrin glue as an adjunct to Limberg
flap may decrease the time to healing compared with Limberg flap
with a suction drain (MD -13.95 days, 95% CI -16.76 days to -
11.14 days) (Analysis 2.1) however this is highly uncertain. The
quality of evidence was very low (downgraded twice for risk of
selection, performance and detection bias and imprecision).
Adverse events
Two studies with 164 participants reported this outcome and they
were pooled using a fixed-effect model (I2 = 0%) (Altinli 2007;
Sözen 2011b). It is uncertain whether using fibrin glue alongside
the Limberg flap affected the incidence of seroma (RR 0.27, 95%
CI 0.05 to 1.61) (Analysis 2.2). The quality of evidence was very
low (downgraded twice for risk of selection, performance and de-
tection bias and for imprecision). The incidence of allergic reac-
tions was not reported in either study.
Secondary outcomes
Infection
The same two studies with 164 participants reported this outcome
and their results were pooled using a fixed-effect model (I2 = 0%)
(Altinli 2007; Sözen 2011b). It is uncertain whether using glue
alongside the Limberg flap affected the incidence of postoperative
infection (RR 0.33, 95% CI 0.04 to 3.11) (Analysis 2.3). The
quality of the evidence was very low (downgraded twice for risk of
selection, performance and detection bias and for imprecision).
Recurrence
One study with 132 participants reported this outcome (Sözen
2011b) and found no cases of recurrence in either group.
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Postoperative pain
The same study involving 132 participants reported this outcome
(Sözen 2011b). Fibrin glue as an adjunct to the Limberg flap may
decrease postoperative pain (measured on a 10 cmVASonday one)
compared with the Limberg flap and a suction drain (median score
with glue as an adjunct was 2, median score without glue was 4;
reported P < 0.001). The quality of evidence was low (downgraded
twice for risk of selection, performance and detection bias).
Time to return to normal activities
The same study involving 132 participants reported this outcome
(Sözen 2011b). Fibrin glue as an adjunct to Limberg flap may
decrease the time taken to return to normal activities compared
with Limberg flap and suction drain (median time with glue was
8 days versus 17 days without glue; reported P < 0.001). The
quality of evidencewas low (downgraded twice for risk of selection,
performance and detection bias).
Quality of life
This outcome was not reported in either study.
Cost difference
This outcome was not reported in either study.
Length of stay
Two studies involving 164 participants reported this outcome and
results were pooled using a random-effects model (I2 = 79%) (
Altinli 2007; Sözen 2011b). It is unclear whether using fibrin glue
with the Limberg flap reduced length of hospital stay compared
with the Limberg flap alone (MD -1.69 days, 95% CI -2.08 days
to -1.29 days) (Analysis 2.4). The quality of evidence was very low
(downgraded for unexplained heterogeneity and twice for risk of
selection, performance and detection bias).
Karydakis flap with and without fibrin glue (one RCT,
50 participants)
Primary outcomes
Healing
This outcome was not reported in the included study (Sözen
2011a).
Adverse events
It is unclear whether using fibrin glue alongside the Karydakis flap
affected the incidence of seroma compared with Karydakis flap
and postoperative drain (Sözen 2011a) (RR 3.00, 95% CI 0.67
to 13.46) (Analysis 3.1). The quality of evidence was very low
(downgraded twice for risk of selection, performance and detec-
tion bias and for imprecision). The incidence of allergy was not
reported in the included study.
Secondary outcomes
Infection
This outcome was not reported in the included study.
Recurrence
The same study (50 participants) reported this outcome (Sözen
2011a). There was no incidence of recurrence in either group.
Postoperative pain
This outcome was not reported in the included study.
Time to return to normal activities
This outcome was not reported in the included study.
Quality of life
This outcome was not reported in the included study.
Cost difference
This outcome was not reported in the included study.
Length of stay
Fibrin glue used alongside the Karydakis flap may reduce hospital
length of stay when compared with Karydakis flap and postoper-
ative drain (Sözen 2011a) (mean length of stay 2 days with glue
compared with 3.7 days without glue; reported P < 0.001). The
quality of evidence was low (downgraded twice for risk of selec-
tion, performance and detection bias).
Sensitivity analysis
Wewere unable to conduct a sensitivity analysis as all the included
studies were at high risk of bias. None of the included studies
reported sponsorship by pharmaceutical companies.
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Other analyses
We were unable to conduct analyses for publication bias or in-
vestigation of heterogeneity due to the low number of included
studies.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Limberg flap plus fibrin glue compared with Limberg flap for pilonidal sinus
Patient or population: Men with pilonidal sinus
Settings: secondary care
Intervention: Limberg f lap plus f ibrin glue
Comparison: Limberg f lap
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Limberg flap Limberg flap plus fibrin
glue
Time to healing (days) The time to healing with Limberg f lap plus f ibrin
glue was on average, 13.95 days quicker (16.76
days to 11.14 days quicker)
- 132 (1 study) ⊕©©©
very low1
The mean time to heal-
ing with Limberg f lap
alone was 22.08 days
Adverse event
(seroma)
61 per 1000 17 per 1000 (3 to 99) RR 0.27 (0.05 to 1.63) 164 (2 studies) ⊕©©©
very low2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; M D: mean dif ference; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.1
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1Downgraded three levels for risk of bias (randomisat ion, blinding and other bias, double downgrade) and imprecision.
2Downgraded three levels for risk of bias (randomisat ion, allocat ion concealment, blinding and other bias, double downgrade)
and imprecision.
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Karydakis flap plus fibrin glue compared with Karydakis flap and drain for pilonidal sinus
Patient or population: Men with pilonidal sinus
Settings: Secondary care
Intervention: Karydakis f lap plus f ibrin glue
Comparison: Karydakis f lap and drain
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Karydakis flap and
drain
Karydakis flap plus fib-
rin glue
Time to healing (days) Not reported
Adverse event
(seroma)
80 per 1000 240 per 1000
(54 to 1000)
RR 3.00 (0.67 to 13.46) 50
(1 study)
⊕©©©
very low1
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; NR: not reported; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded three levels for risk of bias (randomisat ion and blinding, double downgrade) and imprecision.
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D I S C U S S I O N
Summary of main results
Our review included four RCTs of fibrin glue (with or with-
out surgery) compared with surgery alone for pilonidal sinus dis-
ease (Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3). One study evaluated fibrin
glue as monotherapy compared with Bascom’s procedure for peo-
ple with chronic pilonidal sinus disease (Lund 2010). This study
was at high risk of bias for blinding and selective outcome re-
porting (healing). The study was unpublished and did not report
any of our primary outcomes. Although requests for further data
showed that all wounds had healed at follow-up, there were no
data available with which to calculate time to healing. The study
showed that fibrin glue may reduce pain on the first day after the
procedure compared with surgery and may reduce time to return
to normal activities and costs, however these findings are highly
uncertain as the quality of evidence was low or very low. It is highly
uncertain whether using glue compared with surgery affected the
incidence of infection or recurrence at follow-up.
Two studies evaluated fibrin glue as an adjunct to the Limberg
flap compared with the Limberg flap alone in people with chronic
pilonidal sinus disease (Altinli 2007; Sözen 2011b). One of these
studies also used a suction drain in the group without glue (Sözen
2011b). Both studies were at high risk of bias due to inadequate
randomisation and blinding. Very low-quality evidence from one
study (Sözen 2011b) suggested fibrin glue as an adjunct to Limberg
flap may reduce time to healing but this is very uncertain due
to the quality of the evidence (the second study did not report
healing). It is unclear whether fibrin glue as an adjunct to the
Limberg flap reduced the risk of seroma due to the very low-quality
of evidence. Fibrin glue as an adjunct to the Limberg flap may
reduce postoperative pain and time to return to normal activities
although the quality of evidence was low. It is uncertain whether
fibrin glue reduced length of stay when compared with Limberg
flap only due to very low-quality of evidence. Furthermore, it is
unclear whether fibrin glue affected the incidence of infection or
recurrence due to the very low-quality of evidence.
One study evaluated fibrin glue as an adjunct to Karydakis flap
compared with Karydakis flap and postoperative drain in people
with chronic pilonidal sinus disease (Sözen 2011a). This study was
at high risk of bias for randomisation and blinding. This study did
not report the primary outcome of time to healing. It is uncertain
whether fibrin glue as an adjunct to Karydakis flap affected the
incidence of seroma due to the very low-quality of the evidence.
There were no incidences of recurrence in either group. Fibrin
glue as an adjunct to the Karydakis flap may reduce length of stay
although the quality of evidence was low.
Overall completeness and applicability of
evidence
During our searches of databases we identified only four RCTs of
fibrin glue (with or without surgery) versus surgery. We were able
to obtain all the information required from one unpublished study
and the only study which evaluated fibrin glue as monotherapy
(Lund 2010). However, the pre-stated outcome of healing rate was
not reported in the conference abstract. We attempted to contact
one author of two of the included studies for further data although
we received no response (Sözen 2011a; Sözen 2011b). Therefore,
we presented these outcomes as reported within the published
report as median with a P value. We are unaware of any other
studies that were not included in the review.
In terms of external validity, three of the included studies within
the review, which were all conducted in Turkey, evaluated the
use of fibrin glue in men only (Altinli 2007; Sözen 2011a; Sözen
2011b). Therefore, it is unclear how the results from these studies
apply to women and those fromoutside this care setting. Although
male sex is a risk factor for pilonidal sinus, there is no reason
to believe the effects would be different in men and women. In
addition, current studies did not include children and therefore
the efficacy of fibrin glue in this group is unclear. Furthermore,
three studies that evaluated fibrin glue as an adjunct to surgery
excluded participants with recurrent disease, which may limit the
applicability of the evidence to those with primary disease (Altinli
2007; Sözen 2011a; Sözen 2011b).
Quality of the evidence
For fibrin glue monotherapy, the quality of the evidence was low
for pain following the procedure and very low for all other out-
comes. For fibrin glue as an adjunct to Limberg flap, the quality of
the evidence was low for postoperative pain and time to return to
normal activities. However, the quality of evidence was very low
for healing, adverse events, infection and length of stay. For fibrin
glue as an adjunct to Karydakis flap, the quality of evidence was
low for length of stay and very low for adverse events. Severe con-
cerns over risk of bias in all studies evaluating fibrin glue resulted
in double downgrading of evidence (Schünemann 2011b).
We were only able to identify four small RCTs (the sample sizes
ranged from 39 to 164) and therefore most results are highly im-
precise. Two studies were at high risk of selection, performance and
detection bias due to the use of randomisation from an admission
protocol number and the use of postoperative drains which are
highly visible (Sözen 2011a; Sözen 2011b). One of these studies
also had differential lengths of follow up (Sözen 2011b). Another
study was at high risk of selection bias because participants were
allocated based on the day they were seen in clinic although partic-
ipants were likely blinded to treatment allocation (Altinli 2007).
Only one study could be fully assessed for selective outcome re-
porting as this trial was registered in a clinical trials database, how-
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ever the pre-specified outcome of healing rate was not reported
(Lund 2010). This study was at high risk of bias for performance
and detection bias although this would be difficult to address in a
trial of surgery compared with a less invasive intervention, which
may limit the quality of evidence derived from future studies in
this area.
Potential biases in the review process
We used a wide ranging search strategy and were able to retrieve
published and most unpublished data from the studies identified.
One study author did not reply with further information from
two studies (Sözen 2011a; Sözen 2011b), although we were still
able to include data qualitatively. One potential bias in the review
process was that one of the review authors (JL) was also the au-
thor of one of the included studies (Lund 2010). This may have
introduced unconscious bias during risk of bias assessments and
interpretation of the data from this study. We attempted to miti-
gate this as far as possible by performing risk of bias assessments
in duplicate, not involving this particular review author in these
assessments and undergoing thorough peer review to identify any
inappropriate presentation of data or conclusions. Further sources
of bias include the estimation of standard deviation values as these
may not reflect those from the original data. Furthermore, our
decision to input pain data from the first postoperative day may
not reflect important differences in pain at other time points.
Agreements and disagreements with other
studies or reviews
Weare aware of twoprevious systematic reviews onfibrin glue ther-
apy for chronic pilonidal sinus (Handmer 2012; Kayaalp 2016).
However, these reviews included both randomised and observa-
tional studies with no data from unpublished studies. In one of
these reviews (Handmer 2012), in single group cohort studies, the
mean time to return to normal activities was 11 days for fibrin glue
(standard deviation 6 days) which is comparable with our results
for fibrin glue monotherapy (Lund 2010). These observational
studies suggested that the incidence of pilonidal sinus recurrence
after fibrin glue was low (1 in 85 patients; average follow-up ranges
from 4 to 23 months). We also observed a low incidence of recur-
rence in participants treated with fibrin glue (1 in 111 patients;
average follow-up ranges from 2 to 11 months). Our review differs
in only including RCTs which have strengths over single-group
cohort studies, which were included in the previous systematic
reviews (Handmer 2012; Kayaalp 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, the effects of fibrin glue, either as a monotherapy or
as an adjunct to surgery, are uncertain due to the quality of the
evidence. All the included studies were at risk of bias and included
a low number of participants. Low-quality of evidence suggests
fibrin glue monotherapy may be associated with less pain than
surgery on the first post-procedural day although future research
is required to confirm this. We are uncertain about the effects of
fibrin glue as an adjunct to the Limberg flap on time to healing and
adverse events due to the very low-quality of evidence. Fibrin glue
may decrease postoperative pain and time to return to normal ac-
tivities when used alongside the Limberg flap although the quality
of evidence was low. We are uncertain about the effects of fibrin
glue as an adjunct to the Karydakis flap on seroma formation; it
may reduce length of stay relative to surgery alone however this is
highly uncertain due to the low-quality of the evidence. Further,
larger and higher quality randomised controlled trials (RCTs) are
required to inform clinical practice and patient choice.
Implications for research
Future RCTs should be adequately powered with larger numbers
of participants and follow-up, ideally for five years to capture recur-
rence. Future RCTs should measure and report clinically-impor-
tant and patient-relevant outcomes such as time to healing, rates
of recurrence, infection and pain. Future trials should ensure that
robust randomisation and allocation concealment are performed
and, wherever possible, blind participants and outcome assessors
while ensuring low attrition to follow-up to improve internal va-
lidity over the studies published thus far.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Altinli 2007
Methods Parallel, randomised/quasi-RCT. Conducted in secondary care hospital in Turkey
Participants Men, participants with recurrent pilonidal sinus excluded. Age (mean 24.5 years (fibrin
glue) and 22.5 years (control)); BMI (mean 25.7 (fibrin glue) and 25.3 (control)). 32
participants enrolled
Interventions Intervention (16 participants with mean follow-up of 8.5 months): Limberg flap and 6
ml of fibrin glue (Cryoseal FS System)
Control (16 participants with mean follow-up of 8.2 months): Limberg flap
Outcomes Drainage volume (ml)
Length of stay (days)
Infection (%)
Seroma (%)
Mortality (%)
Notes Participants with purulent discharge had 1 week of antibiotics prior to procedure. All
procedures performed under spinal anaesthesia. All participants had postoperative drains.
No funding source reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomised into 2
groups, according to the day the participant
was first seen in the clinic (odd and even
days)
Allocation concealment (selection bias) High risk Participants were randomised into 2
groups, according to the day the participant
was first seen in the clinic (odd and even
days)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants unlikely to know whether
they received the intervention. However, it
would not have been possible to blind the
care giver
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention
23Fibrin glue for pilonidal sinus disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Altinli 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed
Selective reporting (reporting bias) Unclear risk No mention of outcomes in methods or
reference to published protocol
Other bias Low risk Although limited, similar baseline groups.
No mention of sources of funding or con-
flicts of interest
Lund 2010
Methods Parallel, RCT. Unpublished (although abstract previously published). Secondary care
hospital in the UK
Participants Participants excluded if prior allergy to fibrin glue, women not taking contraceptives,
unable to give informed consent, objection to product on moral or religious grounds.
Age (median 29 years (fibrin glue) and 31 years (surgery)); men (50% (fibrin glue) and
47.3% (surgery)). 40 participants enrolled
Interventions Intervention (20 participants): fibrin glue (TISSEEL glue)
Control (20 participants; 19 analysed due to 1 participant lost to follow-up): Bascom’s
procedure
Outcomes Pain (11-point scale on the first 7 days)
Quality of life scores (EQ-5D)
Analgesia usage (assigned points per day, 1 point for simple analgesia and 2 points for
opioid analgesia)
Recurrence (%; defined as return of symptoms)
Infection (%; clinical infection requiring treatment)
Time to return to normal mobility and employment (days)
Cost reduction (GBP).
We included pain score data from day one only as this is the standard time of reporting
for postoperative pain trials. Analgesic usage was measured in this study but we did not
report this as this was not one of oura priori outcomes for the review. Outcomes assessed
in clinic at one and six weeks
Notes Same surgeon operated on participants. All procedures performed under general anaes-
thetic. Study author provided further information. No funding source reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
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Lund 2010 (Continued)
Allocation concealment (selection bias) Low risk Participants were informed by opening of
sequentially-numbered, sealed opaque en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding. Data collected by member of
the surgical team
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one participant in control group lost
to follow-up
Selective reporting (reporting bias) High risk Outcomes stated in original protocol (IS-
RCTN56652573). Healing not reported
in abstract
Other bias Low risk Same surgeon operated on participants.
Similar baseline characteristics
Sözen 2011a
Methods Parallel, RCT/quasi-randomised trial. Secondary care hospital in Turkey
Participants Men with pilonidal disease. Participants were excluded if they had concurrent abscess,
recurrent pilonidal disease or tracts extending more than 3 cm laterally. Age (mean 22.
5 years (fibrin glue) and 24 years (control)); BMI (mean 26 (fibrin glue) and 25.75
(control)). 50 participants enrolled
Interventions Intervention (25 participants): Karydakis flap and 6 ml fibrin glue (CryoSeal FS System)
Control (25 participants); Karydakis flap and drain.
Median follow-up 10.2 months for both groups
Outcomes Length of stay (days)
Seroma (%)
Recurrence (%)
Notes Drains in situ for a median of 3 days. No funding source reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The participants were randomised into 2
groups-drained and fibrin sealant-accord-
ing to the admission protocol number. De-
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Sözen 2011a (Continued)
tails of this protocol number unclear
Allocation concealment (selection bias) Unclear risk The participants were randomised into two
groups-drained and fibrin sealant-accord-
ing to the admission protocol number. De-
tails of this protocol number unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo used. One group had drain
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention. One group had drain
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk Similar baseline groups
Sözen 2011b
Methods Parallel, RCT/quasi-randomised trial. Secondary care hospital in Turkey
Participants Men with pilonidal sinus. Participants were excluded if recurrent disease, large cavity or
if sinus extended lateral to natal cleft or orifice near anus. Age (mean 23.5 years (fibrin
glue) and 25 years (control)); BMI (mean 26 (fibrin glue) and 25.75 (control)). 132
participants enrolled
Interventions Intervention (66 participants with mean follow-up of 2 months): Limberg flap plus 6
ml fibrin glue (CryoSeal FS System)
Control (66 participants with a mean follow-up of 6 months): Limberg flap and suction
drain
Outcomes Postoperative pain (10 cm VAS score)
Time to first mobilisation
Length of stay (days)
Time to return to employment (time from day of surgery to day returned to work or
leisure activities)
Infection (%)
Flap oedema (%)
Wound dehiscence (%)
Seroma (%)
Healing time (days)
Duration of surgery (first incision to last suture)
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Sözen 2011b (Continued)
Notes All procedures performed under spinal anaesthesia. No funding source reported. All
participants followed up weekly until wound healing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The participants were randomised into two
groups, drained and non-drained, accord-
ing to the admission protocol number. Na-
ture of this protocol number unclear
Allocation concealment (selection bias) Unclear risk The participants were randomised into two
groups, drained and non-drained, accord-
ing to the admission protocol number. Na-
ture of this protocol number unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding. Control group had drain
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention. Control group had drain
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed
Selective reporting (reporting bias) Unclear risk No protocol
Other bias High risk Different lengths of follow-up
BMI: body mass index
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Greenberg 2004 No control group
Isik 2014 No control group
Lund 2005 No control group
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(Continued)
Patti 2006 No control group
Seleem 2005 No control group
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D A T A A N D A N A L Y S E S
Comparison 1. Fibrin glue versus Bascom’s procedure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infection 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.16, 2.06]
2 Recurrence 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Median 11 months’
follow-up
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.06, 14.13]
2.2 Median 4.6 years’
follow-up
1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.27, 7.61]
3 Pain (Day 1) 1 39 Mean Difference (IV, Fixed, 95% CI) -2.5 [-4.03, -0.97]
4 Time to return to normal
activities (days)
1 39 Mean Difference (IV, Fixed, 95% CI) -34.8 [-66.82, -2.78]
5 Quality of life (EQ-5D at Day 7) 1 39 Mean Difference (IV, Fixed, 95% CI) 8.0 [-0.10, 16.10]
Comparison 2. Fibrin glue and Limberg flap versus Limberg flap
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Healing (days) 1 132 Mean Difference (IV, Fixed, 95% CI) -13.95 [-16.76, -11.
14]
2 Adverse event (seroma) 2 164 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.05, 1.61]
3 Infection 2 164 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.11]
4 Length of stay (days) 2 164 Mean Difference (IV, Random, 95% CI) -1.69 [-2.08, -1.29]
Comparison 3. Fibrin glue and Karydakis flap versus Karydakis flap
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse event (seroma) 1 50 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.67, 13.46]
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Analysis 1.1. Comparison 1 Fibrin glue versus Bascom’s procedure, Outcome 1 Infection.
Review: Fibrin glue for pilonidal sinus disease
Comparison: 1 Fibrin glue versus Bascom’s procedure
Outcome: 1 Infection
Study or subgroup Fibrin glue Bascom’s procedure Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lund 2010 3/20 5/19 100.0 % 0.57 [ 0.16, 2.06 ]
Total (95% CI) 20 19 100.0 % 0.57 [ 0.16, 2.06 ]
Total events: 3 (Fibrin glue), 5 (Bascom’s procedure)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fibrin glue Favours Bascom’s
Analysis 1.2. Comparison 1 Fibrin glue versus Bascom’s procedure, Outcome 2 Recurrence.
Review: Fibrin glue for pilonidal sinus disease
Comparison: 1 Fibrin glue versus Bascom’s procedure
Outcome: 2 Recurrence
Study or subgroup Fibrin glue Bascom’s procedure Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Median 11 months’ follow-up
Lund 2010 1/20 1/19 100.0 % 0.95 [ 0.06, 14.13 ]
Subtotal (95% CI) 20 19 100.0 % 0.95 [ 0.06, 14.13 ]
Total events: 1 (Fibrin glue), 1 (Bascom’s procedure)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Median 4.6 years’ follow-up
Lund 2010 3/20 2/19 100.0 % 1.43 [ 0.27, 7.61 ]
Subtotal (95% CI) 20 19 100.0 % 1.43 [ 0.27, 7.61 ]
Total events: 3 (Fibrin glue), 2 (Bascom’s procedure)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours fibrin glue Favours Bascom’s
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Analysis 1.3. Comparison 1 Fibrin glue versus Bascom’s procedure, Outcome 3 Pain (Day 1).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 1 Fibrin glue versus Bascom’s procedure
Outcome: 3 Pain (Day 1)
Study or subgroup Fibrin glue Bascom’s procedure
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lund 2010 20 2.5 (2) 19 5 (2.8) 100.0 % -2.50 [ -4.03, -0.97 ]
Total (95% CI) 20 19 100.0 % -2.50 [ -4.03, -0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 1.4. Comparison 1 Fibrin glue versus Bascom’s procedure, Outcome 4 Time to return to normal
activities (days).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 1 Fibrin glue versus Bascom’s procedure
Outcome: 4 Time to return to normal activities (days)
Study or subgroup Fibrin glue Bascom’s procedure
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lund 2010 20 7.2 (51) 19 42 (51) 100.0 % -34.80 [ -66.82, -2.78 ]
Total (95% CI) 20 19 100.0 % -34.80 [ -66.82, -2.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
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Analysis 1.5. Comparison 1 Fibrin glue versus Bascom’s procedure, Outcome 5 Quality of life (EQ-5D at
Day 7).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 1 Fibrin glue versus Bascom’s procedure
Outcome: 5 Quality of life (EQ-5D at Day 7)
Study or subgroup Fibrin glue Bascom’s procedure
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lund 2010 20 39.9 (12.9) 19 31.9 (12.9) 100.0 % 8.00 [ -0.10, 16.10 ]
Total (95% CI) 20 19 100.0 % 8.00 [ -0.10, 16.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 2.1. Comparison 2 Fibrin glue and Limberg flap versus Limberg flap, Outcome 1 Healing (days).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 2 Fibrin glue and Limberg flap versus Limberg flap
Outcome: 1 Healing (days)
Study or subgroup
Fibrin glue
and
Limberg Limberg
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
So¨zen 2011b 66 8.13 (7.88) 66 22.08 (8.59) 100.0 % -13.95 [ -16.76, -11.14 ]
Total (95% CI) 66 66 100.0 % -13.95 [ -16.76, -11.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.72 (P < 0.00001)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours fibrin glue Favours Limberg
Analysis 2.2. Comparison 2 Fibrin glue and Limberg flap versus Limberg flap, Outcome 2 Adverse event
(seroma).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 2 Fibrin glue and Limberg flap versus Limberg flap
Outcome: 2 Adverse event (seroma)
Study or subgroup
Fibrin glue
and
Limberg Limberg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Altinli 2007 0/16 1/16 27.3 % 0.33 [ 0.01, 7.62 ]
So¨zen 2011b 1/66 4/66 72.7 % 0.25 [ 0.03, 2.18 ]
Total (95% CI) 82 82 100.0 % 0.27 [ 0.05, 1.61 ]
Total events: 1 (Fibrin glue and Limberg), 5 (Limberg)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours fibrin glue Favours Limberg
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Analysis 2.3. Comparison 2 Fibrin glue and Limberg flap versus Limberg flap, Outcome 3 Infection.
Review: Fibrin glue for pilonidal sinus disease
Comparison: 2 Fibrin glue and Limberg flap versus Limberg flap
Outcome: 3 Infection
Study or subgroup
Fibrin glue
and
Limberg Limberg Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Altinli 2007 0/16 1/16 50.0 % 0.33 [ 0.01, 7.62 ]
So¨zen 2011b 0/66 1/66 50.0 % 0.33 [ 0.01, 8.04 ]
Total (95% CI) 82 82 100.0 % 0.33 [ 0.04, 3.11 ]
Total events: 0 (Fibrin glue and Limberg), 2 (Limberg)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.33)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours fibrin glue Favours Limberg
34Fibrin glue for pilonidal sinus disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.4. Comparison 2 Fibrin glue and Limberg flap versus Limberg flap, Outcome 4 Length of stay
(days).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 2 Fibrin glue and Limberg flap versus Limberg flap
Outcome: 4 Length of stay (days)
Study or subgroup
Fibrin glue
and
Limberg Limberg
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Altinli 2007 16 2 (0.001) 16 3.9 (0.6) 46.4 % -1.90 [ -2.19, -1.61 ]
So¨zen 2011b 66 2 (0.6) 66 3.5 (0.6) 53.6 % -1.50 [ -1.70, -1.30 ]
Total (95% CI) 82 82 100.0 % -1.69 [ -2.08, -1.29 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 4.79, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 8.45 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours fibrin glue Favours Limberg flap
Analysis 3.1. Comparison 3 Fibrin glue and Karydakis flap versus Karydakis flap, Outcome 1 Adverse event
(seroma).
Review: Fibrin glue for pilonidal sinus disease
Comparison: 3 Fibrin glue and Karydakis flap versus Karydakis flap
Outcome: 1 Adverse event (seroma)
Study or subgroup
Fibrin glue
and
Karydakis Karydakis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
So¨zen 2011a 6/25 2/25 100.0 % 3.00 [ 0.67, 13.46 ]
Total (95% CI) 25 25 100.0 % 3.00 [ 0.67, 13.46 ]
Total events: 6 (Fibrin glue and Karydakis), 2 (Karydakis)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours fibrin glue Favours Karydakis
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Pilonidal Sinus] explode all trees
#2 pilonidal:ti,ab
#3 #1 or #2
#4 MeSH descriptor: [Fibrin Tissue Adhesive] explode all trees
#5 (fibrin or fibrinogen or tissucol or tisseel or tissel or beriplast or crosseal or transglutine or fibrinogen):ti,ab
#6 #4 or #5
#7 #3 and #6 in Trials
Ovid MEDLINE
1 Pilonidal Sinus/
2 pilonidal.ti,ab.
3 1 or 2
4 Fibrin Tissue Adhesive/
5 (fibrin or fibrinogen or tissucol or tisseel or tissel or beriplast or crosseal or transglutine or fibrinogen).ti,ab,rn.
6 4 or 5
7 3 and 6
Ovid Embase
1 Pilonidal Sinus/
2 pilonidal.ti,ab.
3 1 or 2
4 Fibrin Tissue Adhesive/
5 (fibrin or fibrinogen or tissucol or tisseel or tissel or beriplast or crosseal or transglutine or fibrinogen).ti,ab,rn.
6 4 or 5
7 3 and 6
EBSCO CINAHL Plus
S7 S3 AND S6
S6 S4 OR S5
S5 TX (fibrin or fibrinogen or tissucol or tisseel or tissel or beriplast or crosseal or transglutine or fibrinogen)
S4 (MH “Fibrin Tissue Adhesive”)
S3 S1 OR S2
S2 TX pilonidal
S1 (MH “Pilonidal Cyst”)
Clinical trials databases and OpenSIGLE (keywords to maximise sensitivity)
fibrin OR pilonidal
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Appendix 2. ’Risk of bias’ tool
Random sequence generation
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.
Criteria for a judgement of low risk of bias.
The investigators describe a random component in the sequence generation process such as:
• referring to a random number table;
• using a computer random number generator;
• coin tossing;
• shuffling cards or envelopes;
• throwing dice;
• drawing of lots;
• minimisation*.
*Minimisation may be implemented without a random element and this is considered to be equivalent to being random.
Criteria for the judgement of high risk of bias.
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example:
• sequence generated by odd or even date of birth;
• sequence generated by some rule based on date (or day) of admission;
• sequence generated by some rule based on hospital or clinic record number.
Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious.
They usually involve judgement or some method of non-random categorisation of participants, for example:
• allocation by clinician’s judgement;
• allocation by participant’s preference;
• allocation based on the results of a laboratory test or a series of tests;
• allocation by availability of the intervention.
Criteria for the judgement of unclear risk of bias.
• Insufficient information about the sequence generation process to permit judgement of ’low risk’ or ’high risk’.
Allocation concealment
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.
Criteria for a judgement of low risk of bias.
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method,
was used to conceal allocation:
• central allocation (including telephone, web-based and pharmacy-controlled randomisation);
• sequentially numbered drug containers of identical appearance;
• sequentially numbered, opaque, sealed envelopes.
Criteria for the judgement of high risk of bias.
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on:
• use of an open random allocation schedule (e.g. a list of random numbers);
• assignment envelopes used without appropriate safeguards (e.g. envelopes were unsealed, nonopaque or not sequentially
numbered);
• alternation or rotation;
• date of birth;
• case record number;
• any other explicitly unconcealed procedure.
Criteria for the judgement of unclear risk of bias.
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Insufficient information to permit judgement of ’low risk’ or ’high risk’. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement - for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.
Criteria for a judgement of low risk of bias.
Either of the following:
• no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of
blinding;
• blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
Criteria for the judgement of high risk of bias.
Either of the following:
• no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;
• blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the
outcome is likely to be influenced by lack of blinding.
Criteria for the judgement of unclear risk of bias. Any one of the following:
• insufficient information to permit judgement of ’low risk’ or ’high risk’;
• the study did not address this outcome.
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by outcome assessors.
Criteria for a judgement of low risk of bias.
Either of the following:
• no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by
lack of blinding;
• blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.
Criteria for the judgement of high risk of bias.
Either of the following:
• no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;
• blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to
be influenced by lack of blinding.
Criteria for the judgement of unclear risk of bias. Either of the following:
• insufficient information to permit judgement of ’low risk’ or ’high risk’;
• the study did not address this outcome.
Incomplete outcome data
Attrition bias due to the amount, nature or handling of incomplete outcome data.
Criteria for a judgement of low risk of bias.
Any one of the following:
• no missing outcome data;
• reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias);
• missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;
• for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate;
• for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size;
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• missing data have been imputed using appropriate methods.
Criteria for the judgement of high risk of bias.
Any one of the following:
• reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups;
• for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate;
• for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size;
• ’as-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;
• potentially inappropriate application of simple imputation.
Criteria for the judgement of unclear risk of bias. Either of the following:
• insufficient reporting of attrition/exclusions to permit judgement of ’low risk’ or ’high risk’ (e.g. number randomised not stated,
no reasons for missing data provided);
• the study did not address this outcome.
Selective reporting
Reporting bias due to selective outcome reporting.
Criteria for a judgement of low risk of bias.
Either of the following:
• the study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way;
• the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
Criteria for the judgement of high risk of bias.
Any one of the following:
• not all of the study’s pre-specified primary outcomes have been reported;
• one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were
not pre-specified;
• one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect);
• one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;
• the study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Criteria for the judgement of unclear risk of bias.
• Insufficient information to permit judgement of ’low risk’ or ’high risk’. It is likely that the majority of studies will fall into this
category.
Other bias
Bias due to problems not mentioned above.
Criteria for a judgement of low risk of bias.
• The study appears to be free of other sources of bias.
Criteria for the judgement of high risk of bias.
There is at least one important risk of bias. For example, the study:
• had extreme baseline imbalance; or
• had a potential source of bias related to the specific study design used; or
• had an inappropriate influence of funders due to industry-initiated protocols;
• has been claimed to have been fraudulent; or
• had some other problem.
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Or in cluster-randomised trials there is:
• recruitment bias (differential participant recruitment in clusters for different interventions);
• baseline imbalance;
• loss of clusters;
• incorrect analysis;
• comparability with individually randomised trials
Criteria for the judgement of unclear risk of bias.
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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